Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Biogen Alzheimer's Drug Headed For Unfavorable Vote, Says An Analyst's Mock Panel
Investors Business Daily
Mon, 10/19/20 - 10:53 am
Biogen
aducanumab
Alzheimer's disease
FDA
analysts
advisory panels
mock advisory panels
Biogen teams up with gene-editing startup Scribe on ALS program
Pharmaforum
Thu, 10/8/20 - 11:09 am
Scribe Therapeutics
Biogen
ALS
CRISPR
Biogen's all-important Alzheimer's drug enters the review gauntlet
BioPharma Dive
Tue, 09/29/20 - 11:38 pm
Biogen
FDA
aducanumab
Alzheimer's disease
Biogen Conference Led to 20,000 COVID-19 Cases, Study Suggests
BioSpace
Tue, 08/25/20 - 09:39 pm
Biogen
conferences
pandemic
COVID-19
Mylan launches first generic to Tecfidera in multiple sclerosis
Seeking Alpha
Wed, 08/19/20 - 09:26 am
Mylan
generics
Tecfidera
Biogen
MS
multiple sclerosis
Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”
BioSpace
Wed, 08/12/20 - 12:14 am
Biogen
SMA
spinal muscular atrophy
Spinraza
clinical trials
Biogen nabs speedy FDA review for controversial Alzheimer’s drug
Fierce Biotech
Fri, 08/7/20 - 11:00 am
Biogen
aducanumab
Eisai
FDA
Alzheimer's disease
priority review
Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration
Marketwatch
Thu, 08/6/20 - 10:30 am
Denali Therapeutics
Biogen
Parkinson's Disease
Biogen's last-ditch pitch for an injunction to protect Tecfidera is denied, paving way for Mylan generic
Endpoints
Fri, 07/31/20 - 10:46 am
Biogen
Tecfidera
Mylan
generics
Biogen points to COVID-19 for disappointing drug launch
BioPharma Dive
Wed, 07/22/20 - 11:42 pm
Biogen
Vumerity
MS
multiple sclerosis
Biogen's stock rises after big earnings beat, raised outlook
Marketwatch
Wed, 07/22/20 - 10:31 am
Biogen
earnings
Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients
MedCity News
Tue, 07/21/20 - 10:37 am
Biogen
clinical trials
Spinraza
Novartis
Zolgensma
SMA
spinal muscular atrophy
10 most valuable R&D projects in the pharmaceutical industry pipeline
Beckers Hospital Review
Mon, 07/20/20 - 11:49 pm
R&D
drug development
Eli Lilly
Novartis
Argenx
Bristol-Myers Squibb
Vir Biotechnolgy
Biogen
GSK
Iovance
Roche
Alzheimer’s catalysts round off a year dominated by Biogen
EP Vantage
Fri, 07/17/20 - 11:17 am
Alzheimer's disease
Roche
Eli Lilly
AC Immune
Biohaven
Cortexyme
Biogen
Biogen and Eisai trial drug in asymptomatic Alzheimer’s disease
Pharmaforum
Tue, 07/14/20 - 10:31 am
Biogen
Eisai
Alzheimer's disease
amyloid
BAN2401
clinical trials
Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS
BioSpace
Sat, 07/11/20 - 11:45 am
Biogen
ALS
tofersen
BIIB067
clinical trials
Alzheimer’s Drugs on Verge of Becoming Mainstream Medicine, but Early Intervention Still is Needed
BioSpace
Thu, 07/9/20 - 10:27 pm
Alzheimer's disease
drug development
diagnostics
aducanumab
Biogen
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing
Xconomy
Thu, 07/9/20 - 12:12 am
Biogen
FDA
aducanumab
Alzheimer's disease
AstraZeneca, Lilly, Sanofi and others raise prices to start July: report
Fierce Pharma
Wed, 07/8/20 - 10:54 am
AstraZeneca
Eli Lilly
Sanofi
drug pricing
GSK
Biogen
Biogen boosts gene therapy strategy with Harvard pact focused on inherited eye disease
Fierce Biotech
Mon, 07/6/20 - 12:00 pm
Biogen
gene therapy
eye disease
Harvard
Pages
« first
‹ previous
…
20
21
22
23
24
25
26
27
28
…
next ›
last »